Autopsy report · NCT00427427

Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

“lack of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 75 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Jonsson Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Trastuzumab

Participants

75 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (92% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (90% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (90% match in meaning)
• Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
  “Poor accrual” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.